The Activation of Prothrombin Seems to Play an Earlier Role than the Complement System in the Progression of Colorectal Cancer: A Mass Spectrometry Evaluation.
colorectal cancer
complement
mass spectrometry
peptidome
prothrombin
serum
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
11 Dec 2020
11 Dec 2020
Historique:
received:
19
11
2020
revised:
09
12
2020
accepted:
10
12
2020
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Colorectal cancer (CRC) is the second cause of death in men and the third in women. This work deals with the study of the low molecular weight protein fraction of sera from patients who underwent surgery for CRC and who were followed for several years thereafter. MALDI-TOF MS was used to identify serum peptidome profiles of healthy controls, non-metastatic CRC patients and metastatic CRC patients. A multiple regression model was applied to signals preliminarily selected by SAM analysis to take into account the age and gender differences between the groups. We found that, while a signal m/z 2021.08, corresponding to the C3f fragment of the complement system, appears significantly increased only in serum from metastatic CRC patients, a m/z 1561.72 signal, identified as a prothrombin fragment, has a significantly increased abundance in serum from non-metastatic patients as well. The findings were also validated by a bootstrap resampling procedure. The present results provide the basis for further studies on large cohorts of patients in order to confirm C3f and prothrombin as potential serum biomarkers. Thus, new and non-invasive tests might be developed to improve the classification of colorectal cancer.
Identifiants
pubmed: 33322644
pii: diagnostics10121077
doi: 10.3390/diagnostics10121077
pmc: PMC7763171
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : 5x1000 Funds 2013 and 2015
Organisme : Basque Goverment
ID : IT8-11/13
Références
Cancer Res. 2014 Jun 1;74(11):3020-3030
pubmed: 24710407
J Clin Invest. 2006 Jan;116(1):271-84
pubmed: 16395409
J Am Soc Mass Spectrom. 1994 Nov;5(11):976-89
pubmed: 24226387
J Cell Physiol. 2016 Apr;231(4):915-25
pubmed: 26379225
BMC Cancer. 2011 Aug 26;11:381
pubmed: 21871081
Cancer Lett. 2008 Nov 18;271(1):167-77
pubmed: 18691810
Semin Immunol. 2013 Feb;25(1):54-64
pubmed: 23706991
Cancer Res. 2015 Oct 1;75(19):4235-43
pubmed: 26238780
Lancet. 2002 Feb 16;359(9306):572-7
pubmed: 11867112
Chest. 2003 Sep;124(3 Suppl):58S-68S
pubmed: 12970125
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
pubmed: 11309499
Arch Pathol Lab Med. 2009 Oct;133(10):1539-51
pubmed: 19792043
J Biomed Biotechnol. 2012;2012:985020
pubmed: 23091368
Clin Biochem. 2006 Dec;39(12):1144-51
pubmed: 17014837
J Biol Chem. 2000 Mar 3;275(9):6462-8
pubmed: 10692450
J Mass Spectrom. 2010 Jan;45(1):43-50
pubmed: 19899063
Int J Proteomics. 2012;2012:108609
pubmed: 22888427
Front Immunol. 2018 Nov 20;9:2664
pubmed: 30515158
Gut. 2005 Feb;54(2):268-73
pubmed: 15647193
Cancer Res. 2009 Aug 15;69(16):6367-70
pubmed: 19654288
Nature. 2005 Sep 22;437(7058):505-11
pubmed: 16177781
Exp Cell Res. 2018 May 15;366(2):127-138
pubmed: 29551360
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Proteomics. 2010 Jan;10(1):90-8
pubmed: 19882663
BMC Bioinformatics. 2016 Mar 02;17 Suppl 4:61
pubmed: 26961516
Oncotarget. 2017 Jul 26;8(35):59376-59386
pubmed: 28938643
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Br J Surg. 1995 Aug;82(8):1101-4
pubmed: 7648165
Trends Immunol. 2009 Jun;30(6):286-92
pubmed: 19428302
Bioinformatics. 2012 Sep 1;28(17):2270-1
pubmed: 22796955
J Proteomics. 2013 Jun 24;85:44-52
pubmed: 23639844
Int J Cancer. 2015 Nov 15;137(10):2394-402
pubmed: 25994113
J Proteomics. 2018 Feb 20;173:99-106
pubmed: 29242081
Anal Chem. 2004 Mar 15;76(6):1560-70
pubmed: 15018552
Blood. 2000 May 15;95(10):3133-8
pubmed: 10807779
J Gastroenterol. 2001 Dec;36(12):848-50
pubmed: 11777214
CA Cancer J Clin. 2003 Jan-Feb;53(1):44-55
pubmed: 12568443
Mucosal Immunol. 2015 Nov;8(6):1275-84
pubmed: 25736459
Thromb Res. 2018 Apr;164 Suppl 1:S29-S33
pubmed: 29703481
Anal Biochem. 2011 Oct 15;417(2):174-81
pubmed: 21756868
Methods Mol Biol. 2017;1550:339-368
pubmed: 28188540
Clin Colorectal Cancer. 2016 Sep;15(3):e75-92
pubmed: 26792031
Crit Rev Oncol Hematol. 2007 May;62(2):126-36
pubmed: 17293122